Biocon’s insulin to be sold in Mexico

Biopharmaceutical company Biocon Ltd announced on Thursday that its Insulin Glargine has been approved by COFEPRIS, the Mexican health authority, through its partner PiSA Farmaceutica (PiSA). Mexico has been a very important market for Biocon since 2006. Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: “Our Insulin Glargine, will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico.”